AMIX (Autonomix Medical) EBITDA Margin %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AMIX Autonomix Medical Inc AMIX
15 GF Score
Price $5.77
! 2 Warning Signs
View Full Analysis

What is Autonomix Medical EBITDA Margin %?

Autonomix Medical AMIX -12.48% 15 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates AMIX with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Autonomix Medical ranks worse than 122398.9% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Autonomix Medical's EBITDA for the three months ended in Mar. 2026 was $-2.66 Mil. Autonomix Medical's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Autonomix Medical's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.


Autonomix Medical  (NAS:AMIX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Autonomix Medical EBITDA Margin % Related Terms


Autonomix Medical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Autonomix Medical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Autonomix Medical EBITDA Margin % Chart

Autonomix Medical Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EBITDA Margin %
0.00 0.00 0.00 0.00

Autonomix Medical Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AMIX vs BJDX, LUDG, ALURD: EBITDA Margin % Comparison

For the Medical Devices subindustry, Autonomix Medical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Autonomix Medical EBITDA Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Autonomix Medical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Autonomix Medical's EBITDA Margin % falls into.


AMIX
15GF Score
Autonomix Medical Inc AMIX
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Autonomix Medical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Autonomix Medical's EBITDA Margin % for the fiscal year that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-16.703/0
= %

Autonomix Medical's EBITDA Margin % for the quarter that ended in Mar. 2026 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-2.663/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Autonomix Medical (AMIX) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Autonomix Medical and its competitors. According to the industry distribution chart, Autonomix Medical ranks #999999 out of 817 companies in the Medical Devices & Instruments industry.
Is Autonomix Medical's EBITDA Margin % too high?
Autonomix Medical's current EBITDA Margin % is 0.00%. Based on the distribution chart, Autonomix Medical ranks #999999 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Autonomix Medical has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Autonomix Medical's EBITDA Margin % compare to BJDX and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Autonomix Medical ranks #999999 out of 817 companies for EBITDA Margin %. This places Autonomix Medical in the lower half of its industry. The industry median EBITDA Margin % is 7.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Autonomix Medical and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autonomix Medical's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autonomix Medical stock overvalued right now?
Autonomix Medical (AMIX) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Autonomix Medical's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Autonomix Medical (AMIX), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Autonomix Medical Business Description

Address 21 Waterway Avenue, Suite 300, Woodlands, TX, USA, 77380
Autonomix Medical Inc is a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Its platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency (RF) ablation, enabling a sense, treat, verify approach for nerve-targeted therapies. The Company operates in one reportable segment, which is advancing the development of technologies for sensing and treating disorders relating to the nervous system. It is initially focused on developing the technology for patients with pancreatic cancer and believes the technology has the potential to address several indications, including chronic pain management, hypertension, cardiovascular disease, and other nerve-related disorders.
15GF Score

Get the complete analysis for AMIX

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.77
Price